Català | Castellano | English
Previous issues
Digital newsletter of Institut d'Investigació Biomèdica de Bellvitge
Number 144 - 19 April 2016

Home > Calls
Calls
 
Funding Opportunities from the Alzheimer’s Drug Discovery Foundation-LOI-ADDF
Identifier: 140/16
Recipients:
Categorie: Projectes de recerca
Financing entity: 328
OTRI deadline: 05/08/2016
Call aim:

The ADDF offers funding for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. 

  • Preclinical Drug Discovery RFP: seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, related dementias and cognitive aging.
  • Program to Accelerate Clinical Trials (PACT): designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging. It funds biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's, as well as Phase I safety testing and IND-enabling studies to accelerate new drugs into trials.
Duration: <ul> <li><strong>Preclinical Drug Discovery RFP:</strong> 1-2 years</li> <li><strong>Program to Accelerate Clinical Trials (PACT):</strong> varies</li> </ul>
Assignment:
Requirements:

The funding is open to:

  • Researchers, clinicians, and postdoctoral fellows
  • Working in academia and biotechnology companies
  • Based in the U.S. and worldwide
  • Proposals for follow-on funding and renewals are accepted

Restrictions: 

  • Applicants may only submit one proposal per cycle, but a single institution may have multiple applicants apply for funding for different projects.
  • Applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.
Observations:

Letter of Intent (LOI): August 12, 2016

  • Contact Information
  • Scientific Rationale and Background (max 500 words)
  • Project Deliverables (max 300 words)
  • Summary of Key Supporting Data (max 300 words)

You should receive a response to your LOI within two weeks.

 

Invited Full Proposal: September 2, 2016

  • Compound Report Card
  • Preclinical Animal Study Worksheet
  • Budget and Justification Form
  • Biographical Sketch Form
  • Work Plan Delivery Form
  • Business Plan (for biotechs only)
More information:

Find attached the specific program guidelines, if you need more information. 

 

 

Place of presentation:
Cofinancing by the institution: No
Specialist manager:
Dates:
Date of expression of interest: 29/07/2016
OTRI deadline: 05/08/2016
Call deadline: 12/08/2016
Resolution date:
Budget advices (URL):
Calls (URL): Fellowship Website Application website
Other documents: Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials Guidelines    ApoE Therapeutics Innovation Program    Application Instructions    Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials Guidelines    Application Instructions    Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials Guidelines    Application Instructions    Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials Guidelines    Application Instructions    Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials (PACT) Guidelines    Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials (PACT) Guidelines    Pre-clinical drug discovery guidelines    Program to Accelerate Clinical Trials (PACT) Guidelines   
Share/Bookmark
 
Back


Legal notice | Contact